Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models

P Toren, S Kim, T Cordonnier, C Crafter, BR Davies… - European urology, 2015 - Elsevier
Abstract The phosphatidylinositol-4, 5-bisphosphate 3-kinase/Akt (PI3K/Akt) pathway is a
key pathway activated in castrate-resistant prostate cancer (CRPC). This preclinical study …
被引用次数：120 相关文章

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.

P Toren, S Kim, T Cordonnier, C Crafter… - European …, 2014 - europepmc.org
The phosphatidylinositol-4, 5-bisphosphate 3-kinase/Akt (PI3K/Akt) pathway is a key
pathway activated in castrate-resistant prostate cancer (CRPC). This preclinical study …

[引用][C] Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models

P Toren, S Kim, T Cordonnier, C Crafter, BR Davies… - European Urology, 2015 - cir.nii.ac.jp
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate
Cancer in Preclinical Models | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models

P Toren, S Kim, T Cordonnier, C Crafter… - European …, 2015 - pubmed.ncbi.nlm.nih.gov
The phosphatidylinositol-4, 5-bisphosphate 3-kinase/Akt (PI3K/Akt) pathway is a key
pathway activated in castrate-resistant prostate cancer (CRPC). This preclinical study …
[PDF] academia.edu

[PDF][PDF] Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models

P Toren, S Kim, T Cordonnier, C Crafter… - EUROPEAN …, 2015 - academia.edu
Abstract The phosphatidylinositol-4, 5-bisphosphate 3-kinase/Akt (PI3K/Akt) pathway is a
key pathway activated in castrate-resistant prostate cancer (CRPC). This preclinical study …

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models

P Toren, S Kim, T Cordonnier, C Crafter, BR Davies… - European Urology, 2015 - infona.pl
The phosphatidylinositol-4, 5-bisphosphate 3-kinase/Akt (PI3K/Akt) pathway is a key
pathway activated in castrate-resistant prostate cancer (CRPC). This preclinical study …